The number of people with type 2 diabetes has rapidly and remarkably increased throughout Asia, and the rate of increase shows no sign of slowing. People in Asia tend to develop diabetes with a lesser degree of obesity at younger ages, suffer longer with complications of diabetes, and die sooner than people in other regions. Traditional treatment modalities -even multidrug approaches -for type 2 diabetes are often unsatisfactory at achieving glycemic goals as the disease progresses because of a steady, relentless decline in pancreatic b-cell function. To prevent or delayed progression of the disease, we have to understand more about the role of incretin to treat the disease and underlying pathogenesis of type 2 diabetes especially focused on islet biology in this region. GLP-1 receptor agonists not only acutely lower blood glucose resulted by potentiating the insulin secretory response to glucose and suppresses hepatic glucose output by inhibiting glucagon secretion but also engage signaling pathways in the islet beta-cell that lead to stimulation of b-cell replication and inhibition of beta-cell apoptosis. GLP-1 also decreases b-cell workload resulted by reducing peak nutrient absorption and having effects on the central nervous system, resulting in a reduction of food intake. Sitagliptin is an oral, potent, and selective DPP-4 inhibitor. In patients with type 2 diabetes, sitagliptin demonstrated to increase active GLP-1, GIP, insulin level, lower glucagon concentration, and reduce post-glucose load glucose excursion. A once-daily regimen of sitagliptin provides effective improvements in overall glycemic control in monotherapy and combination treatment with metformin, PPAR agents and insulin. Comparing to a SU, sitaglptin provides similar efficacy and superior improvements in measure of b-cell function, and less hypoglycemia & no weight gain. Sitagliptin was well tolerated and have showed negligible side effects so far. Interestingly the glucose lowering effect of sitagliptin was a little superior in Asian subjects including Japan, Korea and India although the exact mechanisms haven't clearly elucidated yet. In conclusion, Sitagliptin have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia. And considerable clinical data support the concept that sitagliptin treatment, alone or in combination with other oral hypoglycemic agents, may potentially reverse the decline in b-cell mass that is characteristic of the natural history of type 2 diabetes. 
